Full-Time

Head of Sales and Process Specialists

Sales, Process Specialists

Posted on 9/23/2025

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Remote in USA

Remote

Category
Sales & Account Management (1)
Required Skills
Sales
SAP Products
Salesforce
Requirements
  • Requires a bachelor’s degree in a Life Sciences discipline. Master’s degree is a plus – MBA is preferable.
  • Minimum 8+ years of experience in building and driving product group sales concepts in a highly technical environment.
  • Minimum 5+ years of leadership experience and managing teams within a sales environment, preferably within Life Science.
  • Relevant technical knowledge and extensive industry knowledge to enable successfully competing in target markets.
  • Analytical approach, ability to analyze and interpret data.
  • Ability to manage complex issues using innovation while respecting processes or adding to the improvement of the same.
  • Excellent communication, presentation, and networking skills at all levels of the organization (internally and externally).
  • Strategic selling knowledge: corporate positioning, high level relationship management.
  • Contracting knowledge: RFP monitoring, proposal preparation, contract award and execution.
  • Leadership skills
  • Proven software skills, e.g. Microsoft Office, SAP, Salesforce.
  • Identification with our core values: Sustainability, Openness, Enjoyment.
Responsibilities
  • Play a pivotal role on the sales leadership team, shaping the organization's commercial direction and strategy, collaborating with senior executives and cross-functional leaders to develop and refine commercial strategies, aligning them with broader business objectives and market dynamics.
  • Champion innovative approaches and initiatives that drive revenue growth, market expansion, and competitive differentiation, positioning the organization for long-term success.
  • Represent the sales function in high-level discussions and decision-making processes, advocating for initiatives that enhance customer value, optimize resource allocation, and drive sustainable business growth.
  • Lead and oversee a team of Sales and Process Specialists (INSO & SUTE) within the biopharmaceutical industry, driving strategic initiatives and achieving organizational objectives.
  • Develop and execute comprehensive sales strategies to maximize revenue growth and market penetration in alignment with company goals.
  • Provide strategic guidance and direction to sales team members, fostering a culture of accountability, innovation, and excellence.
  • Support and engage the team to be part of discussions on in-depth market analysis and customer segmentation to identify emerging trends, opportunities, and threats, informing strategic decision-making and resource allocation.
  • Cultivate and maintain strong relationships with key clients, partners, and industry leaders to drive business development and expand market presence.
  • Drive continuous improvement initiatives by analyzing sales performance metrics, identifying areas for optimization, and implementing effective solutions.
  • Mentor and develop team members, providing ongoing coaching, feedback, and professional development opportunities to enhance their skills and capabilities.
  • Ensure compliance with relevant regulations, policies, and ethical standards, fostering a culture of integrity and compliance throughout the sales organization.

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Goldman Sachs upgrades Sartorius Stedim Biotech to Buy rating.
  • Sartorius achieves 3.5 billion euros sales revenue in 2025.
  • Management forecasts 5-9% sales growth for 2026 with MATTEK contributions.

What critics are saying

  • Thermo Fisher undercuts Sartorius bioreactors, capturing 15-20% market share.
  • Danaher's Cytiva launches Sartocon competitor with 30% higher throughput.
  • Chinese clones replicate Arium Mini at 40% lower cost, eroding Asia sales.

What makes Sartorius unique

  • Sartorius launches Arium Mini Extend for versatile Type 1 water dispensing.
  • Sartorius opens $100M Bioanalytics CoE in Ann Arbor, Michigan.
  • Sartorius partners with Sanofi on downstream process intensification.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Sartorius who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

Sartorius AG
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

INACTIVE